SCHEMBL6690214

SCHEMBL6690214

CC(C)[Si](Oc1ccc(C(=O)Cc2cccnc2)cc1)(C(C)C)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
HPGD P15428 1/20 0.49
IDO1 P14902 6/20 0.48
NAPRT Q6XQN6 1/20 0.47
GAA P10253 1/20 0.46
LMNA P02545 1/20 0.44
MAPK1 P28482 1/20 0.44
CYP19A1 P11511 2/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44
MMP13 P45452 1/20 0.44
PTAFR P25105 3/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
ESR1 P03372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2103554 0.85 STS (0.54) TSHR
SCHEMBL6690529 0.84 CYP19A1 (0.48) LMNACYP19A1MMP13HTTSMN1; SMN2
SCHEMBL6280463 0.82 GAA (0.65) POLBIDO1NAPRTGAALMNA
SCHEMBL6784674 0.80 PLAU (0.48) GAALMNATSHRHTTSMN1; SMN2
SCHEMBL2937613 0.80 NPC1 (0.42) LMNAHTT
SCHEMBL11606129 0.79 GAA (0.61) POLBIDO1NAPRTGAALMNA
SCHEMBL11606857 0.79 MMP13 (0.67) IDO1NAPRTGAALMNAMAPK1
SCHEMBL11603528 0.79 NAMPT (0.60) IDO1NAPRTGAALMNACYP19A1
SCHEMBL6780164 0.79 NPC1 (0.56) HPGDLMNAHTTSMN1; SMN2CYP3A4
SCHEMBL6285165 0.78 LMNA (0.51) POLBHPGDIDO1NAPRTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040044226-A1 Estrogen receptor modulators DININNO FRANK P (US) 2004-03-04 US disclosed
EP-1333827-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2003-08-13 EP disclosed
EP-1328522-A2 ESTROGEN RECEPTOR MODULATORS Merck & Co., Inc. (US) 2003-07-23 EP disclosed
WO-2002032377-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2002-04-25 WO disclosed
WO-2002032373-A2 ESTROGEN RECEPTOR MODULATORS MERCK & CO., INC. (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044226-A1 Estrogen receptor modulators GPER1, ESR2, ESRRA POLB 4443/4885HPGD 1096/4885IDO1 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.